BT2 Suppresses Human Monocytic-Endothelial Cell Adhesion, Bone Erosion and Inflammation

References

• Chen Z, Bozec A, Ramming A, Schett G. Anti-inflammatory and immune-regulatory cytokines in rheumatoid arthritis. Nat Rev Rheumatol. 2019;15(1):9–17. doi:10.1038/s41584-018-0109-2
   PubMed Web of Science ®Google Scholar
• McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med. 2011;365(23):2205–2219. doi:10.1056/NEJMra1004965
   PubMed Web of Science ®Google Scholar
• McInnes IB, Schett G. Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev Immunol. 2007;7(6):429–442. doi:10.1038/nri2094
   PubMed Web of Science ®Google Scholar
• Clough JD. The Cleveland Clinic Guide to Arthritis. New York: Kaplan Publishing; 2009.
   Google Scholar
• Xavier RM, Zerbini CAF, Pollak DF, et al. Burden of rheumatoid arthritis on patients’ work productivity and quality of life. Adv Rheumatol. 2019;59(1):47. doi:10.1186/s42358-019-0090-8
   PubMedGoogle Scholar
• Breedveld FC, Strand V, Boklage SH, et al. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum. 2017;69(1):26–37. doi:10.1002/art.39996
   Google Scholar
• Emery P, Breedveld FC, Hall S, et al. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. Lancet. 2008;372:375–382. doi:10.1016/S0140-6736(08)61000-4
   PubMed Web of Science ®Google Scholar
• Jones G, Sebba A, Gu J, et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis. 2010;69(01):88–96. doi:10.1136/ard.2008.105197
   PubMedGoogle Scholar
• Westhovens R, Robles M, Ximenes AC, et al. Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors. Ann Rheum Dis. 2009;68:1870–1877. doi:10.1136/ard.2008.101121
   PubMed Web of Science ®Google Scholar
• Smolen JS, Aletaha D, Gruben D, et al. Brief report: remission rates with tofacitinib treatment in rheumatoid arthritis: a comparison of various remission criteria. Arthritis Rheum. 2017;69(4):728–734. doi:10.1002/art.39996
   Web of Science ®Google Scholar
• Strand V, Boklage SH, Kimura T, et al. High levels of interleukin-6 in patients with rheumatoid arthritis are associated with greater improvements in health-related quality of life for sarilumab compared with adalimumab. Arthritis Res Ther. 2020;22(1):250. doi:10.1186/s13075-020-02344-3
   PubMed Web of Science ®Google Scholar
• Rubbert-Roth A, Enejosa J, Pangan AL, et al. Trial of upadacitinib or abatacept in rheumatoid arthritis. N Engl J Med. 2020;383(16):1511–1521. doi:10.1056/NEJMoa2008250
   PubMed Web of Science ®Google Scholar
• Siebert S, Tsoukas A, Robertson J, McInnes I, Touyz RM. Cytokines as therapeutic targets in rheumatoid arthritis and other inflammatory diseases. Pharmacol Rev. 2015;67(2):280–309. doi:10.1124/pr.114.009639
   PubMed Web of Science ®Google Scholar
• Paulus YM, Gariano RF. Diabetic retinopathy: a growing concern in an aging population. Geriatrics. 2009;64(2):16–20.
   PubMed Web of Science ®Google Scholar
• van Onna M, Boonen A. The challenging interplay between rheumatoid arthritis, ageing and comorbidities. BMC Musculoskelet Disord. 2016;17(1). doi:10.1186/s12891-016-1038-3
   PubMedGoogle Scholar
• Fazal SA, Khan M, Nishi SE, et al. A clinical update and global economic burden of rheumatoid arthritis. Endocr Metab Immune Disord Drug Targets. 2018;18(2):98–109. doi:10.2174/1871530317666171114122417
   PubMed Web of Science ®Google Scholar
• Li Y, Alhendi AMN, Yeh M-C, et al. Thermostable small-molecule inhibitor of angiogenesis and vascular permeability that suppresses a pERK-FosB/ΔFosB–VCAM-1 axis. Sci Adv. 2020;6(31):eaaz7815. doi:10.1126/sciadv.aaz7815
   PubMed Web of Science ®Google Scholar
• Hess J, Angel P, Schorpp-Kistner M. AP-1 subunits: quarrel and harmony among siblings. J Cell Sci. 2004;117:5965–5973. doi:10.1242/jcs.01589
   PubMed Web of Science ®Google Scholar
• Ye N, Ding Y, Wild C, Shen Q, Zhou J. Small molecule inhibitors targeting activator protein 1 (AP-1). J Med Chem. 2014;57(16):6930–6948. doi:10.1021/jm5004733
   PubMed Web of Science ®Google Scholar
• Asahara H, Fujisawa K, Kobata T, et al. Direct evidence of high DNA binding activity of transcription factor AP-1 in rheumatoid arthritis synovium. Arthritis Rheum. 1997;40(5):912–918. doi:10.1002/art.1780400520
   PubMedGoogle Scholar
• Gad SC, Cassidy CD, Aubert N, Spainhour B, Robbe H. Nonclinical vehicle use in studies by multiple routes in multiple species. Int J Toxicol. 2006;25(6):499–521. doi:10.1080/10915810600961531
   PubMed Web of Science ®Google Scholar
• Dayer JM. The pivotal role of interleukin-1 in the clinical manifestations of rheumatoid arthritis. Rheumatology. 2003;42(Suppl 2):ii3–ii10. doi:10.1093/rheumatology/keg326
   PubMedGoogle Scholar
• Okamoto H, Hoshi D, Kiire A, Yamanaka H, Kamatani N. Molecular targets of rheumatoid arthritis. Inflamm Allergy Drug Targets. 2008;7(1):53–66. doi:10.2174/187152808784165199
   PubMedGoogle Scholar
• Burgazli KM, Venker CJ, Mericliler M, et al. Importance of large conductance calcium-activated potassium channels (BKCa) in interleukin-1b-induced adhesion of monocytes to endothelial cells. Eur Rev Med Pharmacol Sci. 2014;18(5):646–656.
   PubMed Web of Science ®Google Scholar
• Gerszten RE, Lim Y-C, Ding HT, et al. Adhesion of monocytes to vascular cell adhesion molecule-1-transduced human endothelial cells: implications for atherogenesis. Circ Res. 1998;82(8):871–878. doi:10.1161/01.RES.82.8.871
   PubMed Web of Science ®Google Scholar
• Khachigian LM. Collagen antibody-induced arthritis. Nat Protoc. 2006;1(5):2512–2516. doi:10.1038/nprot.2006.393
   PubMed Web of Science ®Google Scholar
• Thiel MJ, Schaefer CJ, Lesch ME, et al. Central role of the MEK/ERK MAP kinase pathway in a mouse model of rheumatoid arthritis: potential proinflammatory mechanisms. Arthritis Rheum. 2007;56(10):3347–3357. doi:10.1002/art.22869
   PubMedGoogle Scholar
• Ballanti P, Minisola S, Pacitti MT, et al. Tartrate-resistant acid phosphate activity as osteoclastic marker: sensitivity of cytochemical assessment and serum assay in comparison with standardized osteoclast histomorphometry. Osteoporos Int. 1997;7(1):39–43. doi:10.1007/BF01623458
   PubMed Web of Science ®Google Scholar
• Cheng T, Wang M, Chen L, et al. Increased expression of CD40/TRAF1 and activation of nuclear factor-κκB-dependent proinflammatory gene expression in collagen-induced arthritis. Scand J Rheumatol. 2018;47(6):455–460. doi:10.1080/03009742.2018.1432684
   PubMed Web of Science ®Google Scholar
• Taylor. I in Background Lesions in Laboratory Animals. (Ed. E.F. McInnes). Edinburgh: Saunders Elsevier; 2012:45–75.
   Google Scholar
• Pober JS. Endothelial activation: intracellular signaling pathways. Arthritis Res. 2002;4(Suppl 3):S109–S116. doi:10.1186/ar576
   PubMedGoogle Scholar
• Schlesinger M, Bendas G. Vascular cell adhesion molecule-1 (VCAM-1)-an increasing insight into its role in tumorigenicity and metastasis. Int J Cancer. 2015;136(11):2504–2514. doi:10.1002/ijc.28927
   PubMed Web of Science ®Google Scholar
• Wilsdon TD, Hill CL. Managing the drug treatment of rheumatoid arthritis. Aust Prescr. 2017;40:51–58. doi:10.18773/austprescr.2017.012
   PubMed Web of Science ®Google Scholar
• de Launay D, van de Sande MGH, de Hair MJH, et al. Selective involvement of ERK and JNK mitogen-activated protein kinases in early rheumatoid arthritis (1987 ACR criteria compared to 2010 ACR/EULAR criteria): a prospective study aimed at identification of diagnostic and prognostic biomarkers as well as therapeutic targets. Ann Rheum Dis. 2012;71(3):415–423. doi:10.1136/ard.2010.143529
   PubMed Web of Science ®Google Scholar
• Karmakar S, Kay J, Gravallese EM. Bone damage in rheumatoid arthritis: mechanistic insights and approaches to prevention. Rheum Dis Clin North Am. 2010;36(2):385–404. doi:10.1016/j.rdc.2010.03.003
   PubMed Web of Science ®Google Scholar
• Scott DL. Radiological progression in established rheumatoid arthritis. J Rheumatol Suppl. 2004;69:55–65.
   PubMedGoogle Scholar
• Schett G, Tohidast-Akrad M, Smolen JS, et al. Activation, differential localization, and regulation of the stress-activated protein kinases, extracellular signal-regulated kinase, c-JUN N-terminal kinase, and p38 mitogen-activated protein kinase, in synovial tissue and cells in rheumatoid arthritis. Arthritis Rheum. 2000;43(11):2501–2512. doi:10.1002/1529-0131(200011)43:11<2501::aid-anr18>3.0.CO;2-K
   PubMed Web of Science ®Google Scholar
• Shiozawa S, Tsumiyama K. Pathogenesis of rheumatoid arthritis and c-Fos/AP-1. Cell Cycle. 2009;8(10):1539–1543. doi:10.4161/cc.8.10.8411
   PubMed Web of Science ®Google Scholar
• Burrage PS, Mix KS, Brinckerhoff CE. Matrix metalloproteinases: role in arthritis. Front Biosci. 2006;11:529–543. doi:10.2741/1817
   PubMed Web of Science ®Google Scholar
• Ahmad M, Theofanidis P, Medford RM. Role of activating protein-1 in the regulation of the vascular cell adhesion molecule-1 gene expression by tumor necrosis factor-alpha. J Biol Chem. 1998;273:4616–4621. doi:10.1074/jbc.273.8.4616
   PubMedGoogle Scholar
• Wang N, Verna L, Hardy S, et al. Adenovirus-mediated overexpression of c-jun and c-fos induces intercellular adhesion molecule-1 and monocyte chemoattractant protein-1 in human endothelial cells. Arterioscler Thromb Vasc Biol. 1999;19(9):2078–2084. doi:10.1161/01.ATV.19.9.2078
   PubMed Web of Science ®Google Scholar
• Navarro-Hernandez RE, Oregon-Romero E, Vázquez-Del Mercado M, et al. Expression of ICAM1 and VCAM1 serum levels in rheumatoid arthritis clinical activity. Association with genetic polymorphisms. Dis Markers. 2009;26(3):119–126. doi:10.1155/2009/510104
   PubMed Web of Science ®Google Scholar
• Littler AJ, Buckley CD, Wordsworth P, et al. A distinct profile of six soluble adhesion molecules (ICAM-1, ICAM-3, VCAM-1, E-selectin, L-selectin and P-selectin) in rheumatoid arthritis. Br J Rheumatol. 1997;36(2):164–169. doi:10.1093/rheumatology/36.2.164
   PubMedGoogle Scholar
• Klimiuk PA, Sierakowski S, Latosiewicz R, et al. Soluble adhesion molecules (ICAM-1, VCAM-1, and E-selectin) and vascular endothelial growth factor (VEGF) in patients with distinct variants of rheumatoid synovitis. Ann Rheum Dis. 2002;61(9):804–809. doi:10.1136/ard.61.9.804
   PubMed Web of Science ®Google Scholar
• Wang L, Ding Y, Guo X, Zhao Q. Role and mechanism of vascular cell adhesion molecule-1 in the development of rheumatoid arthritis. Exp Ther Med. 2015;10(3):1229–1233. doi:10.3892/etm.2015.2635
   PubMed Web of Science ®Google Scholar
• McInnes IB, Buckley CD, Isaacs JD. Cytokines in rheumatoid arthritis — shaping the immunological landscape. Nat Rev Rheumatol. 2016;12(1):63–68. doi:10.1038/nrrheum.2015.171
   PubMed Web of Science ®Google Scholar
• Magyari L, Varszegi D, Kovesdi E, et al. Interleukins and interleukin receptors in rheumatoid arthritis: research, diagnostics and clinical implications. World J Orthop. 2014;5(4):516–536. doi:10.5312/wjo.v5.i4.516
   PubMedGoogle Scholar
• Knevel R, de Rooy DPC, Zhernakova A, et al. Association of variants in IL2RA with progression of joint destruction in rheumatoid arthritis. Arthritis Rheum. 2013;65(7):1684–1693. doi:10.1002/art.37938
   PubMed Web of Science ®Google Scholar
• Katsikis PD, Chu CQ, Brennan FM, Maini RN, Feldmann M. Immunoregulatory role of interleukin 10 in rheumatoid arthritis. J Exp Med. 1994;179(5):1517–1527. doi:10.1084/jem.179.5.1517
   PubMed Web of Science ®Google Scholar
• Chatterjee P, Chiasson VL, Bounds KR, Mitchell BM. Regulation of the anti-inflammatory cytokines interleukin-4 and interleukin-10 during pregnancy. Front Immunol. 2014;5:253. doi:10.3389/fimmu.2014.00253
   PubMed Web of Science ®Google Scholar
• Lubberts E, van den Berg WB. Cytokines in the pathogenesis of rheumatoid arthritis and collagen-induced arthritis. Adv Exp Med Biol. 2003;520:194–202. doi:10.1007/978-1-4615-0171-8_11
   PubMed Web of Science ®Google Scholar
• St Clair EW. Interleukin 10 treatment for rheumatoid arthritis. Ann Rheum Dis. 1999;58(Suppl 1):I99–I102. doi:10.1136/ard.58.2008.i99
   PubMedGoogle Scholar
• Stump KL, Lu LD, Dobrzanski P, et al. A highly selective, orally active inhibitor of janus kinase 2, CEP-33779, ablates disease in two mouse models of rheumatoid arthritis. Arthritis Res Ther. 2011;13(2):R68. doi:10.1186/ar3329
   PubMed Web of Science ®Google Scholar